ARA-290 increased nerve fiber density in two small Phase 2 trials

What is ARA-290?

ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the helix-B surface region of erythropoietin (EPO) to keep EPO's tissue-protective signaling without its red cell production. Erythropoietin does two things that used to be treated as one. It binds a classical EPOR homodimer on red blood cell precursors, which drives red cell production.

EPO is also proposed to signal through a separate heteroreceptor complex, EPOR paired with CD131 (the beta-common receptor). That complex shows up on neurons, glial cells, and other tissue types and is linked to cytoprotective and anti-inflammatory signaling rather than hematopoiesis. Researchers named this second pathway the innate repair receptor (IRR).

The helix-B region is the part of EPO proposed to interact with the IRR rather than the classical EPOR dimer. ARA-290's design logic is to keep the tissue-protective signaling, drop the erythropoietic activity, and avoid the clotting and blood-viscosity concerns that make full-length EPO unsuitable for chronic non-anemia use. The rationale, selective innate repair receptor agonism without classical EPOR dimer activation, is sound and consistent with the absence of hematologic effects in the ARA-290 trials. The ARA-290 evidence profile summarizes where the compound stands.

What did animal studies of ARA-290 show?

In a rat nerve-injury model, ARA-290 reduced mechanical and cold allodynia for up to 20 weeks after dosing stopped, coupled with suppressed microglial reactivity in the spinal cord ^[5]. That finding offers a plausible explanation for effects that outlast a short course: in the model, ARA-290 modulated a central inflammatory response implicated in maintaining neuropathic pain states rather than masking pain in the moment.

The hypothesis is coherent and well supported. A coherent hypothesis is still not a demonstrated clinical effect in humans at scale. The distinction matters more for ARA-290 than almost anywhere else in the peptide space, because human data exist to check the hypothesis against, and the checking has been limited.

How many human trials of ARA-290 exist?

Four small randomized trials, with 22, 28, 64, and roughly 48 participants, make up essentially the entire human evidence base for ARA-290. Three enrolled people with sarcoidosis-associated small fiber neuropathy, and one enrolled people with type 2 diabetes and painful neuropathy, all dosed for about 28 days under clinical monitoring.

The cited clinical exposure is limited to small diagnosed-neuropathy populations treated briefly, and it does not establish benefits or long-term safety in healthy users. Some corneal nerve density endpoints were exploratory or secondary rather than pre-registered primary outcomes, which matters for interpreting the strength of the reported p-values.

Does ARA-290 reduce neuropathic pain?

ARA-290 improved validated neuropathic symptom scores in three small trials, in sarcoidosis-associated small fiber neuropathy and in type 2 diabetes with painful neuropathy ^[1]⁠^[2]⁠^[4].

The first pilot trial, in sarcoidosis-associated small fiber neuropathy (n=22), gave ARA-290 intravenously three times weekly. At four weeks, the Small Fiber Neuropathy Screening List score improved significantly versus placebo (a change of -11.5 vs -2.9 points, p<0.05), with no safety concerns ^[1]. That endpoint was a self-reported symptom inventory in a tiny sample: a legitimate positive signal and nothing more. The second sarcoidosis trial (n=28) also found improved symptoms, temperature sensitivity, and six-minute walk distance versus placebo ^[2].

The fourth trial extended the signal beyond sarcoidosis into a much more common condition: type 2 diabetes with painful neuropathy (n≈48), on the 4 mg subcutaneous daily, 28-day protocol. PainDetect neuropathy scores improved versus placebo, and HbA1c (p=0.002) and the lipid profile also improved significantly ^[4]. The metabolic effect was not the primary hypothesis going in, which makes it either an interesting secondary finding or a reason for caution about how many endpoints were tested.

Whether these symptom gains translate to meaningful pain relief outside those specific conditions is untested.

Does ARA-290 regenerate nerves?

ARA-290 produced statistically significant, objectively measured increases in corneal and intraepidermal nerve fibers in two small trials, the strongest part of its evidence base ^[2]⁠^[3].

The second sarcoidosis trial (n=28) switched to daily subcutaneous dosing for 28 days and added an objective outcome: corneal nerve fiber area measured by confocal microscopy. Corneal nerve fiber area rose a statistically significant 14.5% over baseline (p=0.022) ^[2]. That trial moved ARA-290 beyond "another peptide that improves a symptom score," because an imaging-based increase in nerve fiber density is a different kind of evidence from a questionnaire. It is why ARA-290 rates higher than most peptides at a comparable evidence stage.

The largest and most rigorous trial to date, a Phase 2b dose-ranging study in sarcoidosis-associated neuropathy (n=64), replicated and extended that finding. The 4 mg/day dose produced a placebo-corrected increase in corneal nerve fiber area of 697 µm² (95% CI 159 to 1236, p=0.012) and a significant increase in regenerating intraepidermal nerve fibers marked by GAP-43, a protein associated with axonal growth (p=0.035) ^[3]. GAP-43 positivity flags newly sprouting fibers rather than pre-existing ones, so this trial most directly supports "true nerve regeneration" language over symptom masking.

In the diabetes trial, the corneal nerve density increase was concentrated in patients who started below normal density ^[4].

Why is ARA-290 still unapproved?

ARA-290 has no Phase 3 trial: all available data are Phase 2, small (n=22 to 64), and short (28 days of dosing). The originating sponsor's broader program stalled rather than progressing toward registration, as far as the public record shows.

A decade of small positive trials that never converts into a large confirmatory trial is a pattern consistent with three explanations: real but modest effect sizes; endpoints that impress in exploratory analysis but do not hold up in a larger, harder-to-game trial; or a corporate and funding history that has nothing to do with the science. The public record does not distinguish cleanly between them. Claims that the stall definitely proves ARA-290 does not work, or definitely proves it is only corporate neglect, are guesses.

ARA-290's biological plausibility has consistently outrun its demonstrated clinical effect size, which is unusual for a peptide with this much cult enthusiasm behind it. The evidence grade is moderate, not strong. For another peptide whose secondary endpoint signals did not carry a pivotal trial, see davunetide's failed trial in progressive supranuclear palsy.

Is the 4 mg daily ARA-290 protocol supported by trials?

The 4 mg subcutaneous daily ARA-290 protocol circulating online is the dose two trials used in diabetic neuropathy and sarcoidosis neuropathy ^[3]⁠^[4]. It is not a dose validated for general use, healthy users, or any other purpose.

Online protocols extrapolate from that limited evidence to people the trials never enrolled. Applying the corneal nerve density findings to a general audience is exactly the kind of leap the source trials never tested and cannot support.

Is ARA-290 safe?

No serious safety signals emerged in the ARA-290 trials, but the safety database is small, short, and limited to sick populations under monitoring. Long-term safety beyond 28 days in a monitored trial setting is unstudied.

ARA-290's selective mechanism sounds low-risk. "Sounds low-risk mechanistically" and "has an established safety record" are different claims, and only the second requires a large, long trial, which does not exist.

Anyone sourcing ARA-290 outside a clinical trial also takes on unstudied product-quality risk: purity, sterility, and accurate labeling are not guaranteed outside regulated manufacturing. The guide on how to read a peptide certificate of analysis covers what a lab report can show.

What is still unknown about ARA-290?

The ARA-290 trials studied people with an existing, diagnosed small fiber neuropathy from sarcoidosis or diabetes, dosed for 28 days under clinical monitoring. Outside that setting, the gaps are wide:

• Healthy users. None of the cited trials enrolled healthy users, so benefits and long-term safety in healthy people are not established.
• Longer courses. No published trial data cover dosing courses longer than 28 days.
• Other conditions. No published trial data cover other neuropathic pain conditions.
• "Nerve health" claims. No published trial data support the vague "nerve health" or general anti-inflammatory framing that circulates in forum and marketing content.